CClinicalTrials.gg
CompletedNCT03375905Updated Sep 19, 2019

Effectiveness and Safety of cNEP in Ethnic Japanese With Obstructive Sleep Apnea

An interventional study of cNEP in Obstructive Sleep Apnea, sponsored by Sommetrics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-09-19.

Sponsored by Sommetrics, Inc. · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The aim of this study is to evaluate the effectiveness and safety of cNEP (continuous negative external pressure) for the treatment of obstructive sleep apnea during two weeks of home use in subjects of Japanese ethnicity.

02

Conditions studied

  • Obstructive Sleep Apnea

Keywords

  • ethnic Japanese
03

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • both parents ethnically Japanese, or one parent Japanese and the other east-Asian
  • PSG (polysomnogram) done within the previous 12 months that shows an AHI of 10-50/hr and \<80% of apneas and hypopneas are obstructive
  • cNEP collar fits and is well-tolerated

Key exclusion Criteria:

  • BMI >34
  • abnormalities in neck structure
  • sleep disturbance other than obstructive sleep apnea
  • serious medical illness
  • pregnancy
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    cNEP

    cNEP treatment

    Device: cNEP

Interventions

  • DevicecNEP

    subjects with OSA will be treated with the cNEP device with the goal of reducing the number of apneas and hypopneas

    Also known as: continuous negative external pressure

05

What researchers measure

Primary outcomes

  1. proportion of sustained responders

    reduction of AHI of \>50% and to \<15/hr from qualifying PSG

    Time frame: two weeks after initiation of treatment

Secondary outcomes

  1. proportion of initial responders

    reduction of AHI of \>50% and to \<15/hr from qualifying PSG

    Time frame: at PSG 1, one day

  2. AHI comparison with qualifying PSG

    apnea-hypopnea index

    Time frame: one day, on three separate study occasions

  3. ODI comparison with qualifying PSG

    oxygen desaturation index

    Time frame: one day, on three separate study occasions

  4. SpO2 <90% comparison with qualifying PSG

    oxygen desaturation index \<90%

    Time frame: one day, on three separate study occasions

  5. CGI of sleep

    clinical global impressions of sleep, comparing 3-month baseline with end of two weeks of treatment

    Time frame: three months, and two weeks, respectively

  6. CGI of satisfaction with the cNEP device

    clinical global impressions of the cNEP device

    Time frame: after two weeks of treatment

  7. Treatment-emergent adverse events

    tabulation of treatment-emergent adverse events

    Time frame: two weeks

06

Study locations

1 site
  • The Sleep Lab
    Kaneohe, Hawaii 96744, United States
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03375905
Lead sponsor
Sommetrics, Inc.
Responsible party
Sponsor
First posted
Dec 18, 2017
Start date
Dec 7, 2017
Primary completion
Mar 28, 2019
Completion
Apr 26, 2019
Last update
Sep 19, 2019

Study contacts

Jamil S Sulieman, MD
principal investigator · The Sleep Lab, Kaneohe, HI

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion